









Markets
/
Stocks
/
nasdaq-acog
/

Alpha Cognition Inc

ACOG

5.800USD

+0.100+1.75%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

92.93MMarket Cap

LossP/E TTM



Alpha Cognition Inc

5.800

+0.100+1.75%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Alpha Cognition Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Alpha Cognition Inc's Score

Industry at a Glance

Industry Ranking

102 / 159

Overall Ranking

265 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

18.000

Target Price

+215.79%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Alpha Cognition Inc Highlights

StrengthsRisks

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -3.65, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.74M shares, decreasing 21.78% quarter-over-quarter.

Held by Paul Tudor Jones

Star Investor Paul Tudor Jones holds 70.00K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 7.09, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.09

Change



Financials

8.78

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.06

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

5.70

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.82

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Alpha Cognition Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 6.06, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -3.65, which is -57.99% below the recent high of -1.53 and -127.21% above the recent low of -8.30.

Score

Industry at a Glance

Previous score

6.06

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 102/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Alpha Cognition Inc is 18.00, with a high of 18.00 and a low of 18.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

18.000

Target Price

+215.79%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Alpha Cognition Inc

ACOG

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 6.54, which is lower than the Pharmaceuticals industry's average of 6.89. Sideways: Currently, the stock price is trading between the resistance level at 7.21 and the support level at 5.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.41

Change

0.13

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.148

Sell

RSI(14)

29.469

Sell

STOCH(KDJ)(9,3,3)

11.274

Oversold

ATR(14)

0.494

Low Volatility

CCI(14)

-145.608

Sell

Williams %R

92.261

Oversold

TRIX(12,20)

-0.825

Sell

StochRSI(14)

25.495

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

6.088

Sell

MA10

6.449

Sell

MA20

6.795

Sell

MA50

7.659

Sell

MA100

8.569

Sell

MA200

7.481

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.74. The latest institutional shareholding proportion is 27.45%, representing a quarter-over-quarter decrease of 49.02%. The largest institutional shareholder is Paul Tudor Jones, holding a total of 70.00K shares, representing 0.33% of shares outstanding, with 23.36% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Solas Capital Management, LLC

1.28M

-8.42%

AWM Investment Company, Inc.

1.10M

Besser (James E)

1.00M

Ikarian Capital LLC

917.87K

-5.17%

Cable Car Capital LLC

869.00K

+0.06%

Sphera Funds Management Ltd.

376.65K

-36.91%

Cawkell (Kenneth Anthony)

358.12K

+63.92%

Mertz (Leonard Powell)

324.01K

+44.95%

Havens (John P)

285.59K

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.41, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 2.61. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.